Neon Therapeutics, Inc. Common Stock
NTGN
NTGN was delisted on the 5th of May, 2020.
44 hedge funds and large institutions have $99.7M invested in Neon Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 6 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
2% less funds holding
Funds holding: 45 → 44 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
41% less capital invested
Capital invested by funds: $169M → $99.7M (-$69.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.49M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$385K |
| 3 |
State Street
Boston,
Massachusetts
|
+$326K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$253K |
| 5 |
Morgan Stanley
New York
|
+$243K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$2.19M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$916K |
| 4 |
CC
Casdin Capital
New York
|
-$525K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$427K |
NTGN Hedge Fund Activity: Q4 2018 in Review
44 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Neon Therapeutics, Inc. Common Stock (NTGN) for Q4 2018, worth a combined $99.7M — down 41% from $169M a quarter earlier.
Fund positioning in NTGN was balanced in Q4 2018: 6 funds opened new positions, 6 closed out, 18 added to existing stakes and 11 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $3.49M. The largest seller was Hillhouse Investment Management, cutting an estimated $2.19M.
- 44 institutional investors held Neon Therapeutics, Inc. Common Stock (NTGN) as of Q4 2018, down from 45 in Q3 2018.
- Funds reported $99.7M of Neon Therapeutics, Inc. Common Stock stock for Q4 2018, down 41% quarter-over-quarter.
- 6 funds opened new Neon Therapeutics, Inc. Common Stock positions in Q4 2018 and 6 closed out, a net change of 0 holders.
- The largest Neon Therapeutics, Inc. Common Stock buyer in Q4 2018 was ArrowMark Colorado Holdings, an estimated $3.49M added.
- The largest Neon Therapeutics, Inc. Common Stock seller in Q4 2018 was Hillhouse Investment Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q4 2018.